InvestorsHub Logo
Followers 14
Posts 730
Boards Moderated 0
Alias Born 12/09/2013

Re: willyw post# 588

Friday, 09/12/2014 8:58:26 AM

Friday, September 12, 2014 8:58:26 AM

Post# of 2933
This is one of those larger factors I refer to. (payors)

The 2017-18 approval time frame isn't a big deal.
Far more important are the efficacy, safety, and duration and cost of the treatment(and compared to what the competition offers).

https://twitter.com/tylerhcarter/status/510401384018370560/photo/1

Around 2018 the field could also start to get more crowded, but the numbers to be treated are still huge.
I see no reason ENTA and some other players who are not yet in the spotlight to be able to carve out their share of the HCV mmarket.

It would seem to me that if the 2nd generation program was competitive ENTA will be in for the full ride.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News